B & T Capital Management DBA Alpha Capital Management Acquires 3,009 Shares of Kenvue Inc. (NYSE:KVUE)

B & T Capital Management DBA Alpha Capital Management lifted its holdings in shares of Kenvue Inc. (NYSE:KVUEFree Report) by 1.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 200,967 shares of the company’s stock after buying an additional 3,009 shares during the period. B & T Capital Management DBA Alpha Capital Management’s holdings in Kenvue were worth $4,291,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Leo Wealth LLC boosted its holdings in shares of Kenvue by 0.3% during the 3rd quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock valued at $3,507,000 after acquiring an additional 481 shares during the last quarter. Alerus Financial NA boosted its holdings in Kenvue by 0.3% in the third quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock worth $4,426,000 after purchasing an additional 491 shares during the last quarter. Massmutual Trust Co. FSB ADV grew its position in Kenvue by 6.2% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company’s stock worth $194,000 after purchasing an additional 492 shares during the period. Wolff Wiese Magana LLC raised its stake in Kenvue by 0.7% during the 3rd quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock valued at $1,781,000 after buying an additional 501 shares during the last quarter. Finally, Marathon Capital Management lifted its holdings in shares of Kenvue by 0.3% during the 2nd quarter. Marathon Capital Management now owns 149,699 shares of the company’s stock valued at $2,722,000 after buying an additional 514 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Kenvue Stock Down 0.4 %

Shares of NYSE:KVUE opened at $21.11 on Friday. The company has a 50-day moving average price of $22.42 and a 200 day moving average price of $21.66. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46. The company has a market cap of $40.46 billion, a price-to-earnings ratio of 38.37, a PEG ratio of 1.99 and a beta of 1.46.

Kenvue (NYSE:KVUEGet Free Report) last released its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The firm had revenue of $3.90 billion for the quarter, compared to the consensus estimate of $3.92 billion. During the same quarter in the previous year, the company posted $0.31 EPS. The company’s revenue for the quarter was down .4% compared to the same quarter last year. As a group, equities research analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be paid a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.89%. The ex-dividend date is Wednesday, February 12th. Kenvue’s dividend payout ratio is currently 149.09%.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on KVUE shares. Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $25.00 to $24.00 in a research note on Thursday, December 12th. Royal Bank of Canada raised Kenvue from a “hold” rating to a “moderate buy” rating in a research note on Monday, December 9th. Bank of America boosted their price objective on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd. Barclays decreased their target price on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Friday. Finally, Piper Sandler upgraded shares of Kenvue from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $21.00 to $26.00 in a research report on Monday, January 6th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, Kenvue presently has a consensus rating of “Hold” and an average target price of $23.08.

Get Our Latest Stock Report on KVUE

About Kenvue

(Free Report)

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

Further Reading

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUEFree Report).

Institutional Ownership by Quarter for Kenvue (NYSE:KVUE)

Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.